Neoadjuvant therapy reduces node positivity but does not confer survival benefit versus up‐front resection for resectable intrahepatic cholangiocarcinoma: A propensity‐matched analysis
Journal of Surgical Oncology · 2024
DOI: 10.1002/jso.27743 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Chase J Wehrle und 15 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic Foundation, Digestive Diseases and Surgery Institute, Section of Hepato-Pancreato-Biliary Surgery, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Neoadjuvant Therapy, Propensity Score. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Neoadjuvant systemic therapy (NAST) is a treatment option for intrahepatic cholangiocarcinoma (iCCA), though its impact on short‐term oncologic outcomes and long‐term survival remains relatively unknown.
Methods
The National Cancer Database (NCDB) between 2004 and 2019 was queried for patients with reportedly resectable (Stage I−IIIB) iCCA who received curative‐intent resection with lymphadenectomy. Propensity matching was performed between groups based on the use of NAST and groups were compared for overall survival (OS) and oncologic outcomes, including nodal harvest, rate of node positivity, rate of positive margins, and administration of adjuvant therapy.
Results
Two thousand and five hundred ninety‐six patients met inclusion criteria; 364 (14%) received NAST versus 1763 (68%) up‐front resection. After matching, 332 pairs of patients were matched between NAST and no NAST. Patients receiving NAST had a greater nodal harvest (OR = 1.26 [1.09−1.88]; p < 0.001) and a lower rate of node positivity (OR = 0.67 [0.49−0.63]; p < 0.001). Patients without NAST were more likely to complete adjuvant systemic therapy (OR = 0.45 [0.33−0.62]; p < 0.001). However, patients receiving NAST had no OS benefit after resection compared to those who did not receive NAST (median OS 48.3 ± 5.3 vs. 38.8 ± 3.7 months; p = 0.160). Node‐positive disease (OR = 2.10 [1.78−2.45]; p < 0.001) conferred the greatest risk for reduced OS followed by positive‐margin resection (OR = 1.42 [1.21−1.47]; p < 0.001) and increasing T‐stage (OR = 1.34 [1.21−1.47]; p < 0.001).
Conclusion
NAST for iCCA was associated with improved quality of oncologic resection but did not confer an OS benefit versus up‐front resection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cleveland Clinic Foundation, Digestive Diseases and Surgery Institute, Section of Hepato-Pancreato-Biliary Surgery, Cleveland, Ohio, USA.
- Department of Surgical Oncology, Edward-Elmhurst Health, Elmhurst, Illinois, USA.
- Cleveland Clinic Foundation, Section of Liver Transplantation, Cleveland, Ohio, USA.
Zitieren
APA
Wehrle, C. J., Chang, J., Woo, K., Gross, A., Naples, R., Dahdaleh, F., Stackhouse, K., Kim, J., Augustin, T., Simon, R., Joyce, D., Kwon, D. C. H., Miller, C., Walsh, R. M., Aucejo, F., & Naffouje, S. (2024). Neoadjuvant therapy reduces node positivity but does not confer survival benefit versus up‐front resection for resectable intrahepatic cholangiocarcinoma: A propensity‐matched analysis. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27743
Vancouver
Wehrle CJ, Chang J, Woo K, Gross A, Naples R, Dahdaleh F, et al. Neoadjuvant therapy reduces node positivity but does not confer survival benefit versus up‐front resection for resectable intrahepatic cholangiocarcinoma: A propensity‐matched analysis. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27743
BibTeX
@article{Wehrle2024,
author = {Wehrle, Chase J and Chang, Jenny and Woo, Kimberly and Gross, Abby and Naples, Robert and Dahdaleh, Fadi and Stackhouse, Kathryn and Kim, Jaekeun and Augustin, Toms and Simon, Robert and Joyce, Daniel and Kwon, David C H and Miller, Charles and Walsh, R Matthew and Aucejo, Federico and Naffouje, Samer},
title = {Neoadjuvant therapy reduces node positivity but does not confer survival benefit versus up‐front resection for resectable intrahepatic cholangiocarcinoma: A propensity‐matched analysis},
journal = {Journal of Surgical Oncology},
year = {2024},
doi = {10.1002/jso.27743}
}
EUVIMED